Uncategorized
Eleven Biotherapeutics fails to meet primary endpoint in topical allergic conjunctivitis trial
Eleven Biotherapeutics’ lead investigational drug EBI-005 did not meet the primary endpoint of reducing mean ocular itching compared with vehicle control in a modified environmental exposure chamber model, according to a company press release.Giving top-line data from a phase 2 investigation of the drug candidate in patients with mild to severe allergic conjunctivitis, Eleven Biotherapeutics reported statistically significant improvement in the secondary endpoint of mean change from baseline in patient-reported ocular itching compared to vehicle control in a conjunctival allergen provocation test (CAPT) model.